|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 5/01/19 Ekso Bionics Holdings, Inc. 10-Q 3/31/19 85:6.4M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 447K
2: EX-10.1 Material Contract HTML 429K
3: EX-10.2 Material Contract HTML 77K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
14: R1 Document And Entity Information HTML 47K
15: R2 Condensed Consolidated Balance Sheets HTML 113K
16: R3 Condensed Consolidated Balance Sheets HTML 45K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 74K
and Comprehensive Loss
18: R5 Consolidated Statements of Stockholders' Equity HTML 76K
19: R6 Condensed Consolidated Statements of Cash Flows HTML 120K
20: R7 Organization HTML 35K
21: R8 Basis of Presentation and Summary of Significant HTML 62K
Accounting Policies and Estimates
22: R9 Accumulated Other Comprehensive Income (Loss) HTML 29K
23: R10 Fair Value Measurements HTML 71K
24: R11 Inventories, net HTML 35K
25: R12 Revenue Recognition HTML 66K
26: R13 Investment in Unconsolidated Affiliate HTML 35K
27: R14 Accrued Liabilities HTML 41K
28: R15 Long-Term Debt HTML 44K
29: R16 Lease Obligations HTML 48K
30: R17 Capitalization and Equity Structure HTML 70K
31: R18 Stock-based Compensation HTML 83K
32: R19 Income Taxes HTML 26K
33: R20 Commitments and Contingencies HTML 31K
34: R21 Net Loss Per Share HTML 43K
35: R22 Segment Disclosures HTML 56K
36: R23 Related Party Transactions HTML 28K
37: R24 Subsequent Events HTML 28K
38: R25 Basis of Presentation and Summary of Significant HTML 95K
Accounting Policies and Estimates (Policies)
39: R26 Accumulated Other Comprehensive Income (Loss) HTML 29K
(Tables)
40: R27 Fair Value Measurements (Tables) HTML 69K
41: R28 Inventories, net (Tables) HTML 37K
42: R29 Revenue Recognition (Tables) HTML 57K
43: R30 Accrued Liabilities (Tables) HTML 42K
44: R31 Long-Term Debt (Tables) HTML 36K
45: R32 Lease Obligations (Tables) HTML 40K
46: R33 Capitalization and Equity Structure (Tables) HTML 58K
47: R34 Stock-based Compensation (Tables) HTML 84K
48: R35 Net Loss Per Share (Tables) HTML 45K
49: R36 Segment Disclosures (Tables) HTML 58K
50: R37 Organization (Details) HTML 37K
51: R38 Basis of Presentation and Summary of Significant HTML 40K
Accounting Policies and Estimates (Details)
52: R39 Accumulated Other Comprehensive Income (Loss) HTML 34K
(Details)
53: R40 Fair Value Measurements - Fair Value Hierarchies HTML 38K
(Details)
54: R41 Fair Value Measurements - Change in Level 3 HTML 38K
(Details)
55: R42 Inventories, net (Details) HTML 38K
56: R43 Revenue Recognition - Deferred Revenue (Details) HTML 42K
57: R44 Revenue Recognition - Deferred Revenue Activity HTML 30K
(Details)
58: R45 Revenue Recognition - Additional Information HTML 40K
(Details)
59: R46 Revenue Recognition - Performance Obligations HTML 36K
(Details)
60: R47 Revenue Recognition - Disaggregation of Revenue HTML 45K
(Details)
61: R48 Investment in Unconsolidated Affiliate (Details) HTML 62K
62: R49 Accrued Liabilities - Schedule of Accrued HTML 41K
Liabilities (Details)
63: R50 Accrued Liabilities - Product Maintenance and HTML 28K
Warranty (Details)
64: R51 Long-Term Debt - Additional Information (Details) HTML 55K
65: R52 Long-Term Debt - Debt Repayment (Details) HTML 46K
66: R53 Lease Obligations - Additional Information HTML 41K
(Details)
67: R54 Lease Obligations - Future Minimum Payments HTML 50K
(Details)
68: R55 Capitalization and Equity Structure - Additional HTML 85K
Information (Details)
69: R56 Capitalization and Equity Structure - Warrants HTML 58K
(Details)
70: R57 Capitalization and Equity Structure - Valuation HTML 41K
Assumptions (Details)
71: R58 Stock-based Compensation - Additional Information HTML 47K
(Details)
72: R59 Stock-based Compensation - Stock Option Activity HTML 79K
(Details)
73: R60 Stock-based Compensation - Valuation Assumptions HTML 34K
(Details)
74: R61 Stock-based Compensation - RSU Activity (Details) HTML 43K
75: R62 Stock-based Compensation - Compensation Expense HTML 33K
(Details)
76: R63 Commitments and Contingencies (Details) HTML 38K
77: R64 Net Loss Per Share - Earnings Per Share (Details) HTML 32K
78: R65 Net Loss Per Share - Antidilutive Shares (Details) HTML 33K
79: R66 Segment Disclosures - Operating Segments (Details) HTML 41K
80: R67 Segment Disclosures - Geographical Segments HTML 31K
(Details)
81: R68 Related Party Transactions (Details) HTML 29K
82: R69 Subsequent Events (Details) HTML 38K
84: XML IDEA XML File -- Filing Summary XML 149K
83: EXCEL IDEA Workbook of Financial Reports XLSX 83K
8: EX-101.INS XBRL Instance -- ekso-20190331 XML 1.43M
10: EX-101.CAL XBRL Calculations -- ekso-20190331_cal XML 203K
11: EX-101.DEF XBRL Definitions -- ekso-20190331_def XML 556K
12: EX-101.LAB XBRL Labels -- ekso-20190331_lab XML 1.55M
13: EX-101.PRE XBRL Presentations -- ekso-20190331_pre XML 898K
9: EX-101.SCH XBRL Schema -- ekso-20190331 XSD 165K
85: ZIP XBRL Zipped Folder -- 0001549084-19-000004-xbrl Zip 201K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.; |
(2) | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
(4) | The
company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the company’s internal
control over financial reporting; and |
(5) | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
/s/ John F. Glenn | |
Principal Financial Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/1/19 | 8-K | ||
| For Period end: | 3/31/19 | |||
| List all Filings | ||||